Project Detail
Interagency Autism Coordinating Committee (IACC) logo
Office of Autism Research Coordination (OARC) logo

Investigation of postnatal drug intervention's potential in rescuing the symptoms of fragile X syndrome in adult mice  

Knockdown of metabotropic glutamate receptor 5 (mGluR5) has been shown to reverse symptoms of fragile X syndrome in a mouse model. This study investigates whether postnatal intervention can ameliorate or reverse symptoms using both genetic and pharmacological approaches to inhibit mGluR5 after birth. This research will inform both the basic question of whether there is a critical period necessary for mGluR5 inhibition as a therapy as well as test whether a specific mGluR5 antagonist may have promise as a treatment. Project Status
ONGOING

2010

Funder Autism Science Foundation
Fiscal Year Funding $0.00
Current Award Period 2009-2010
Project Number n/a
Principal Investigator Sidorov, Michael
Received ARRA Funding? No
Strategic Plan Question Question 2: How Can I Understand What Is Happening? (Biology)
Subcategory Molecular Pathways
Strategic Plan Objective Green dot: Objective has greater than or equal to the recommended funding. 2SD. Launch three studies that target improved understanding of the underlying biological pathways of genetic conditions related to autism (e.g. Fragile X, Rett syndrome, tuberous sclerosis complex) and how these conditions inform risk assessment and individualized intervention by 2012. IACC Recommended Budget: $9,000,000 over 5 years.
Federal or Private? Private
Institution Massachusetts Institute of Technology
State/Country Massachusetts
Web Link 1 Investigation of postnatal drug intervention's potential in rescuing the symptoms of fragile X syndrome in adult mice (External web link)
Web Link 2 No URL available.
Web Link 3 No URL available.
New! History/Related Projects Investigation of postnatal drug intervention's potential in rescuing the symptoms of fragile X syndrome in adult mice | $30,000.00 | 2009 | Project number unavailable